Kamal Ghorui
Dr Reddy’s Laboratories Ltd is foraying into the hormone replacement therapy (HRT) segment in India with the acquisition of the trademarks and related assets for Progynova and Cyclo‑Progynova from UK-headquartered Mercury Pharma Group Limited for a consideration of $32.15 million (approx Rs 295 crore).The move is aimed at strengthening its gynaecology portfolio and serving as a platform to expand in the HRT segment that is used to manage symptoms associated with estrogen deficiency and menopause, Dr Reddy’s said in a regulatory filing on Wednesday.While Progynova (estradiol valerate) is an oral HRT indicated for the treatment of estrogen deficiency symptoms and prevention of postmenopausal osteoporosis, Cyclo‑Progynova (estradiol valerate and norgestrel) is a combined HRT that includes both estrogen and progestogen components and is used for the treatment of estrogen deficiency symptoms.MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr Reddy’s, said the acquisition would act as a “spearhead” for the company’s expansion into HRT, leveraging the company’s market access to broaden reach and bring “first-in-class” treatment options closer to patients.As per IQVIA MAT December 2025 data, the brand clocked sales of Rs 100 crore.
